Mirati Therapeutics, Inc. financial data

Symbol
MRTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
3545 Cray Court, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q3 2023 - Nov 6, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 695 % -32.4%
Quick Ratio 6.35 %
Debt-to-equity 21.1 % +46.3%
Return On Equity -82.2 % -36%
Return On Assets -67.8 % -28.5%
Operating Margin -2 K % +68.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 70.1 M shares +21.8%
Common Stock, Shares, Outstanding 70.1 M shares +21.8%
Entity Public Float 3.7 B USD -50%
Common Stock, Value, Issued 70 K USD +20.7%
Weighted Average Number of Shares Outstanding, Basic 65 M shares +15.6%
Weighted Average Number of Shares Outstanding, Diluted 65 M shares +15.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 38.2 M USD +224%
Research and Development Expense 507 M USD -6.86%
General and Administrative Expense 213 M USD +79.4%
Operating Income (Loss) -765 M USD -2.68%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -162 M USD +6.58%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -726 M USD +1.64%
Earnings Per Share, Basic -12.2 USD/shares +9.01%
Earnings Per Share, Diluted -12.2 USD/shares +9.01%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 259 M USD -13.4%
Marketable Securities, Current 718 M USD -20.4%
Accounts Receivable, after Allowance for Credit Loss, Current 14.7 M USD
Inventory, Net 20.2 M USD
Assets, Current 1.04 B USD -15.5%
Property, Plant and Equipment, Net 16 M USD -10.4%
Operating Lease, Right-of-Use Asset 35.1 M USD -3.82%
Other Assets, Noncurrent 24.8 M USD +17.9%
Assets 1.13 B USD -13.3%
Employee-related Liabilities, Current 34.5 M USD +20.8%
Accrued Liabilities, Current 99.4 M USD -7.55%
Liabilities, Current 137 M USD +8.18%
Operating Lease, Liability, Noncurrent 42.2 M USD -4.29%
Other Liabilities, Noncurrent 3.66 M USD +24.1%
Liabilities 183 M USD +5.29%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.55 M USD +74.7%
Retained Earnings (Accumulated Deficit) -2.98 B USD -32.3%
Stockholders' Equity Attributable to Parent 946 M USD -16.2%
Liabilities and Equity 1.13 B USD -13.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -190 M USD -18.5%
Net Cash Provided by (Used in) Financing Activities 1.73 M USD -31.7%
Net Cash Provided by (Used in) Investing Activities 195 M USD +294%
Common Stock, Shares Authorized 100 M shares 0%
Common Stock, Shares, Issued 70.1 M shares +21.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.67 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 259 M USD -13.4%
Deferred Tax Assets, Valuation Allowance 620 M USD +47.2%
Deferred Tax Assets, Gross 628 M USD +46.4%
Operating Lease, Liability 51.5 M USD +12.2%
Depreciation 2.8 M USD +55.6%
Payments to Acquire Property, Plant, and Equipment 269 K USD -76.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -721 M USD +4.3%
Property, Plant and Equipment, Gross 23 M USD +23.5%
Operating Lease, Liability, Current 8.02 M USD +11.9%
Deferred Tax Assets, Operating Loss Carryforwards 255 M USD -14.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Additional Paid in Capital 3.92 B USD +15.9%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 1 M USD
Depreciation, Depletion and Amortization 1.08 M USD +70.9%
Deferred Tax Assets, Net of Valuation Allowance 8.23 M USD +4.04%
Share-based Payment Arrangement, Expense 193 M USD +21.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%